Soligenix, Inc. · NASDAQ:SNGX
Soligenix — Technical Presentation (August 2016)
36 slides from Soligenix's technical presentation, August 2016
Slide 1: Dusquetide: Innate Defense Regulation as a Novel Approach to Antibiotic-Resistant Infection
Dusquetide: Innate Defense Regulation as a Novel Approach to Antibiotic- Resistant Infection BARDA TechWatch Meeting August 2016 1
Slide 2: IDR Program Status
IDR Program Status • cGMP - quality dusquetide available in IV formulation: – Potential for intramuscular (self-administered) formulation – Stability at refrigerated and room temperature conditions – Manufactured 3 GMP batches to date • 84-subject Phase 1 healthy volunteer study completed: – Placebo
Slide 3: IDR Discovery
IDR Discovery • Research at UBC on antimicrobial peptides, e.g., Human LL-37 (Finlay, Hancock, et al.); • IDR-1 synthesized 2001: – Modeled around cathelicidins, indolicidins, defensins, etc.; • Protects animals from lethal bacterial infection but has no intrinsic antibacterial activity: – “Innate D
Slide 4: Overview: Innate Defense System
Overview: Innate Defense System • First line of defense against injuries and infections – Includes anatomical barriers such as skin, oral and lower GI tract and respiratory mucosa • Major involvement in activation of adaptive immune responses • A nonspecific response (as opposed to adaptive immunity
Slide 5: Overview: Innate Defense Regulators
Overview: Innate Defense Regulators • Innate Defense Regulators (IDRs) were designed to: – Selectively enhance host protective systems without triggering harmful inflammation – Operate independent of pathogen or insult Innate • IDRs provide an opportunity to: Defense Regulators – Ameliorate tissue d
Slide 6: Sequestosome-1 (p62)
Sequestosome-1 (p62) TNFR TLR • Sequestosome-1 (p62) is a multi- TRIF MyD88 domain adaptor p62 protein C UB • Operates as a A TRAF6 TBS signal integrator in RIP1 RIP1 ZZ innate defense PB1 P pathways PKC N p38 Ub P IB P C/EBP C/EBP • Expressed in most NF-B cell types P NF-B C/EBP NF-B C/EBP
Slide 7: SGX94 Targets Sequestosome-1 (p62)
SGX94 Targets Sequestosome-1 (p62) • SGX94 specifically binds to the ZZ domain of p62 TNFR TL R TRIF MyD88 • Selectively stabilizes TNFα-induced p62 C p62-RIP1 complex formation ‒ No effect on TNFα-induced p62- UB PKCξ complex formation A TBS TRAF6 • Specifically modulates downstream pathways by act
Slide 8: Preclinical Overview
Preclinical Overview • Broad-spectrum anti-infective activity established including gram+, gram- and antibiotic resistant pathogens – MRSA bacteremia – IM MRSA – IP K. pneumoniae Anti-Infective – IP B. pseudomallei + IN B. pseudomallei – PO P. aeruginosa • Enhances survival and bacterial clearance w
Slide 9: Broad Spectrum Anti-Infective
Broad Spectrum Anti-Infective IDRs are Effective Against a Wide Range of Pathogens SGX94 Reduces Bacteria (gram positive) SGX94 Increases Survival (gram negative) 8 100 7 75 Log CFU/ml %Survival 6 50 5 Detection p<0.001 Limit 25 4 0 Control SGX94 Control SGX94 STUDY DESIGN: STUDY DESIGN: • Gram Posi
Slide 10: Efficacy in Melioidosis
Efficacy in Melioidosis Gram-negative, intracellular, antibiotic-resistant infection Peritoneal Infection Lung Infection S G X 5 0 + D o x y ( M S T = 6 .5 d ) 100 100 S G X 25+D oxy 80 80 S G X 5 0 + S a lin e % s u r v iv a l % s u r v iv a l S a lin e + D o x y ( M S T = 3 d ) 60 60 S a lin e + S
Slide 11: MRSA Bacteremia
MRSA Bacteremia Therapeutic & Prophylactic Effect, Prolonged Survival, Extended PD Effect Single dose prolongs survival for up to 21 d Extended pharmacodynamic effect 100 100 Saline Saline -4h *p=.002 Percent survival Percent survival 80 Linezolid 80 Linezolid SGX94 50mg/kg SGX94 -4h* 60 60 SGX94 -4
Slide 12: Increased Survival in a Gram-Negative Infection
Increased Survival in a Gram-Negative Infection Efficacy despite Neutropenia in Gram-negative Pseudomonas aeruginosa infection Mucosal weight 100 Saline 0.25 *p<.001 Mucosal weight (gm) Percent survival 80 Cefepime *p<.001 SGX94 0.20 SGX94 Mean +/- 95%CI 60 0.15 40 0.10 20 0.05 0 0 100 200 300 0.00
Slide 13: Complements Antibiotics
Complements Antibiotics Enhances survival and bacterial clearance SGX94 enhances survival when antibiotic SGX94 enhances bacterial clearance when therapy is inadequate antibiotic therapy is inadequate 100 9 p < 0.01 p < 0.01 8 Survival 80 Log CFU/g *p < 0.01 7 60 *p < 0.01 SGX94 + Vanc *p < 0.01 *p
Slide 14: Epithelial Damage & Infection
Epithelial Damage & Infection SGX94 Significantly Reduced Ulceration and Swelling of the Epithelial Barrier Linezolid (12mg/kg) administered PO at 0 and 24h after infection Ulceration Score at 48 h 2.0 Ulceration Score 1.5 1.0 0.5 Saline administered IV 4 hrs prior to infection 0.0 Swelling Score at
Slide 15: Chemokine Responses at Site of Infection
Chemokine Responses at Site of Infection Rantes (CCL5) Increased at 3 hrs IP-10 (CXCL10) Increased at 3 hrs 400 p < 0.05 400 p=0.05 CXCL10 (pg/mL) CCL 5 (pg/mL) 300 300 200 200 100 100 0 0 Saline SGX94 Saline SGX94 TNF Decreased at 24 hrs p <0.05 STUDY DESIGN: 40 • Female CD-1 mice were injected IP
Slide 16: Selectively Increased Macrophage Recruitment
Selectively Increased Macrophage Recruitment Macrophages Increased Neutrophils Unchanged 2000 2500 p < 0.05 Macrophage Count Neutrophil Count 1500 2000 1500 1000 1000 500 500 0 0 IP IV IP IV IP IV IP IV e e 4 4 e e 4 4 lin lin X9 X9 lin lin X9 X9 Sa Sa SG SG Sa Sa SG SG STUDY DESIGN: • Female CD-1 m
Slide 17: Pathobiology of Mucositis
Pathobiology of Mucositis Radiation Normal Initiation Amplification Ulceration Healing Epithelium Epithelium Sub-Mucosa Fibroblast Basal Cell Inflammatory Cell Blood Vessel Chemotherapy Innate response to Damage-Associated Molecules Ref: S. Sonis 2004 17
Slide 18: Radiation-Induced Mucositis
Radiation-Induced Mucositis SGX94 50 %Animal Days with a Score of >/= 3 40 p=.027 46% reduction p=.006 30 p<.001 20 10 0 e 33 n 3d cl ad 0- Q hi R n Ve 3d of ad Q s R ay of D s Summary: ay D • SGX94 dosed every third day (red group) or on days of radiation treatment (green group) show similar effica
Slide 19: Mucositis in DSS IBD Model
Mucositis in DSS IBD Model DSS + Steroid Treatment DSS + SGX94 Treatment Mean Endoscopy Colitis Score (+/- SEM) SGX94 Days 0, 3, 6, 9,12 SGX94 Days 3, 6, 9,12 3 2 *p=0.025 *p=0.009 *p=0.032 *p=0.006 1 *p=0.015 0 Data from BioModels, LLC. 0 7 14 21 Day Summary: Daily Prednisolone or Budesonide reduce
Slide 20: Non-Clinical Program
Non-Clinical Program • Toxicology Species – Mouse: established pharmacology – Non-human primate: similarity of immunology • Toxicology program – 14-day GLP toxicology with daily IV administration Toxicology / • Safety Pharmacology: Safety – CV/pulmonary study in NHP Pharmacology – No carcinogenicity
Slide 21: Pharmacokinetic Profile
Pharmacokinetic Profile Mouse – 60 min IV Infusion at 20 mg/kg NHP – 60IMX942 minPlasma Concentration (ng/mL) IV Infusion at 80 mg/kg Mean Plasma Concentration (ng/ml) 100000 Mean Plasma Concentration (ng/mL) Mean (Males) 10000 Mean (Females) 1000 100 10 1 0.1 0.01 0 5 10 15 20 25 30 Time (hr) Time
Slide 22: No Interference with Antibiotics
No Interference with Antibiotics No interference with the efficacy of antibiotics as measured by survival and clinical signs Antibiotics classes : Antibiotic Infection models Dosing regimen Aminoglycoside: Gentamicin 1) K. pneumoniae (ATCC10031) Gentamicin: 3 mg/kg IV x1 peritonitis IMX942: 20 or 50
Slide 23: Clinical Overview
Clinical Overview • Single Ascending Dose in healthy volunteers: – 18-55 years; Target 30% females, non-childbearing potential – All cohorts: 6 active and 2 placebo. Blinded / randomized – Six dose levels planned and completed (0.15 – 8 mg/kg) – Drug well tolerated • Multiple Ascending Dose: – 7- da
Slide 24: Phase 1 PK: MAD
Phase 1 PK: MAD • Dose proportional increase in Cmax and exposure (AUC) Mean Plasma Conc (ng/ml) • Tmax is dose independent • Cmax, Tmax and AUC not affected by multiple administrations • Consistent with mouse and monkey findings Time (h) 24 North et al. 2016
Slide 25: Pharmacodynamic (PD) marker analysis
Pharmacodynamic (PD) marker analysis • Demonstrate that IDRs pose no risk of a “Cytokine Storm” Objective • Obtain evidence of drug effect to enable future drug dose selection Procedures • Blood incubated with LPS for 4 hr, then tested for 10 markers by Rules-Based Medicine Inc. – IL-1a, IL-1b, IL-1
Slide 26: Phase 1 Dose Selection
Phase 2 Dose Selection • Activity in oral mucositis in preclinical models at human equivalent dose of 1-2 mg/kg. – Higher dose levels could not be assessed in rodents. • Anti-inflammatory markers indicated 1-2 mg/kg as the most effective dose. IL - 1 R a /IL - 1 R a t io T N F R II / T N F R a t
Slide 27: Phase 2 Study Design
Phase 2 Study Design • Enrolled 111 Head and neck (H&N) cancer patients planned to receive at least 55 Gy radiation and either weekly (30-40 mg/m2) or every 3rd week (80-100 mg/m2) cisplatin – 96 patients received at least 55 Gy irradiation and constituted the primary mITT analysis population • Dose
Slide 28: Clinically Meaningful Results
Clinically Meaningful Results D u r a t io n o f S e v e r e O r a l M u c o s it is • 50% decrease in duration of severe Duration Severe OM (WHO3) OM 40 p = 0 .0 9 9 • Reduced infection rates D u r a t io n W H O 3 M e d ia n 9 5 % C I 30 • Does not protect tumor (“complete 18 days 22 days (D
Slide 29: More Disease = Bigger Effect Size
More Disease = Bigger Effect Size • Subjects with higher incidence of OM experienced more benefit from SGX942 (dusquetide) – Reduced duration of ulcerative (WHO2) OM also observed D u r a tDuration io n o f SSevere e v e r e OM: r a t io n Duration O r a l M u c o sDituis o f U lc e Ulcerative r a
Slide 30: IDR Potential
IDR Potential • Effective independent of bacterial identification – Gram negative or Gram positive – Intracellular or Extracellular – Antibiotic sensitive or Antibiotic resistant • Complementary to antibiotics • Effective despite immunosuppression (e.g., in absence of T-cells or in leukopenic animal
Slide 31: Intellectual Property and Market Exclusivity
Intellectual Property and Market Exclusivity • Novel drug substance – composition of matter (expiry: 2026-2029) • Method of use: – Infection (expiry: 2026) – Oral mucositis (filing date: 2013) 31
Slide 32: Who is at risk for mucositis?
Who is at risk for mucositis? • Close to 500,000 US patients per year suffer from from mucositis during cancer therapy – and the incidence is increasing • Oral mucositis in HNC cancer is estimated at a $500M+ market Breast Breast CRC 14% 14% CRC 21% 21% Stem Cell Stem cell Transplant transplant 4% 4
Slide 33: Potential Commercial Market Opportunities
Potential Commercial Market Opportunities Patients at risk of Mucosal Barrier Failure and Infection / Inflammation: Blue = anti-inflammatory action Green = anti-infective action Melioidosis Hospital-Associated Pneumonia Gram-negative Radiation-induced infections VAP dermatitis Radiation-induced fibr
Slide 34: Infectious Disease: Barriers to Entry
Infectious Disease: Barriers to Entry • IDRs are first-in-class with an unique mechanism – Phase 2 study has mitigated the risk that the novel biology in rodents would not translate to the clinical setting. • Infectious disease clinical trials are large and expensive – Driven by the inability to acc
Slide 35: Conclusions
Conclusions • Advantages of IDRs in infectious disease: – Broad-spectrum activity, including gram-negative intracellular infections – Activity against antibiotic resistant strains – Safe product without generation of resistance: can be used prophylactically, preemptively and therapeutically – Likely
Slide 36: Key References
Key References • Scott et al, 2007: Infectious disease applications of IDRs (prototype compound) http://www.nature.com/nbt/journal/v25/n4/full/nbt1288.html • Yu et al 2009: Identification of target protein and molecular signaling (prototype compound) http://www.jbc.org/content/284/52/36007.long • No